Roivant Sciences Ltd
ROIV25.820USD
+4.680+22.14%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
18.32BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Roivant Sciences Ltd Unternehmen
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltd Informationen
BörsenkürzelROIV
Name des UnternehmensRoivant Sciences Ltd
IPO-datumDec 03, 2020
CEOVenker (Eric)
Anzahl der mitarbeiter750
WertpapierartOrdinary Share
GeschäftsjahresendeDec 03
Addresse7Th Floor, 50 Broadway
StadtLONDON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited Kingdom
PostleitzahlSW1H 0DB
Telefon4412955950
Websitehttp://roivant.com/
BörsenkürzelROIV
IPO-datumDec 03, 2020
CEOVenker (Eric)
Führungskräfte von Roivant Sciences Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+14524.00%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.50M
--
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
+112255.00%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
100.84K
+1040.00%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.62K
+487.00%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
--
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
41.26K
+761.00%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
37.59K
-148860.00%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
--
-20494245.00%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+14524.00%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.50M
--
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
+112255.00%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
100.84K
+1040.00%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.62K
+487.00%
Umsatzaufteilung
FY2025Q1
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
VTAMA
55.13M
0.00%
Nach RegionUSD
Name
Umsatz
Anteil
United States
55.13M
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
VTAMA
55.13M
0.00%
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Dexcel Pharma Technologies, Ltd.
14.37%
Fidelity Management & Research Company LLC
8.49%
Ramaswamy (Vivek)
6.58%
The Vanguard Group, Inc.
5.86%
Morgan Stanley Investment Management Inc. (US)
5.68%
Andere
59.02%
Aktionäre
Aktionäre
Anteil
Dexcel Pharma Technologies, Ltd.
14.37%
Fidelity Management & Research Company LLC
8.49%
Ramaswamy (Vivek)
6.58%
The Vanguard Group, Inc.
5.86%
Morgan Stanley Investment Management Inc. (US)
5.68%
Andere
59.02%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
30.17%
Investment Advisor/Hedge Fund
19.57%
Hedge Fund
14.79%
Corporation
14.37%
Individual Investor
10.31%
Private Equity
8.79%
Research Firm
1.60%
Pension Fund
0.49%
Venture Capital
0.45%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
723
545.88M
78.49%
-26.29M
2025Q3
690
526.70M
77.13%
-109.19M
2025Q2
673
776.63M
112.42%
-147.35M
2025Q1
676
776.88M
113.63%
-136.03M
2024Q4
645
780.70M
109.07%
-147.12M
2024Q3
601
789.51M
107.30%
-83.47M
2024Q2
564
721.13M
95.89%
-110.95M
2024Q1
518
776.24M
96.43%
-47.46M
2023Q4
449
787.20M
97.95%
-13.44M
2023Q3
421
794.31M
100.15%
+12.61M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Dexcel Pharma Technologies, Ltd.
102.85M
14.79%
--
--
Jul 01, 2025
Fidelity Management & Research Company LLC
60.73M
8.73%
+5.24M
+9.44%
Sep 30, 2025
Ramaswamy (Vivek)
47.07M
6.77%
-1.00
-0.00%
Dec 15, 2025
The Vanguard Group, Inc.
38.72M
5.57%
-521.41K
-1.33%
Sep 30, 2025
Morgan Stanley Investment Management Inc. (US)
40.65M
5.85%
+7.28M
+21.82%
Sep 30, 2025
SB Investment Advisers (UK) Limited
40.32M
5.8%
-19.64M
-32.76%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
35.76M
5.14%
+233.57K
+0.66%
Sep 30, 2025
QVT Financial LP
28.08M
4.04%
-1.30M
-4.42%
Nov 19, 2025
Viking Global Investors LP
23.59M
3.39%
-10.64M
-31.09%
Sep 30, 2025
Rubric Capital Management LP
20.00M
2.88%
-370.34K
-1.82%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco S&P MidCap 400 Pure Growth ETF
3.56%
Adaptiv Select ETF
2.91%
Virtus LifeSci Biotech Products ETF
2.79%
State Street SPDR S&P Biotech ETF
2.67%
WisdomTree US Value Fund
2.3%
ProShares Ultra Nasdaq Biotechnology
1.73%
Goldman Sachs Future Health Care Equity ETF
1.73%
Direxion Daily S&P Biotech Bull 3X Shares
1.41%
Invesco Nasdaq Biotechnology ETF
1.33%
WisdomTree BioRevolution Fund
1.3%
Mehr Anzeigen
Invesco S&P MidCap 400 Pure Growth ETF
Anteil3.56%
Adaptiv Select ETF
Anteil2.91%
Virtus LifeSci Biotech Products ETF
Anteil2.79%
State Street SPDR S&P Biotech ETF
Anteil2.67%
WisdomTree US Value Fund
Anteil2.3%
ProShares Ultra Nasdaq Biotechnology
Anteil1.73%
Goldman Sachs Future Health Care Equity ETF
Anteil1.73%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil1.41%
Invesco Nasdaq Biotechnology ETF
Anteil1.33%
WisdomTree BioRevolution Fund
Anteil1.3%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
